Neuronal beta 2-containing nicotinic acetylcholine receptor (beta2-nAChR) (beta2-nAChR)

Neuronal beta 2-containing nicotinic acetylcholine receptors (beta2-nAChRs) are pentameric ligand-gated ion channels primarily located in the central nervous system [UniProt: P17676]. These receptors, most commonly found as the alpha4beta2 heteromer, play a critical role in mediating fast excitatory neurotransmission and modulating the release of other neurotransmitters such as dopamine, GABA, and glutamate [PubMed: 10658631]. They are the primary high-affinity binding sites for nicotine in the brain and are essential for the reinforcing properties of tobacco [PubMed: 9430587]. Dysregulation or genetic mutations in the beta 2 subunit (CHRNB2) are linked to conditions such as nicotine dependence, Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE), and cognitive deficits in Alzheimer's disease [NIH: CHRNB2; StatPearls: NBK542274]. Pharmacological targeting of these receptors involves agonists and partial agonists for smoking cessation and cognitive enhancement, as well as antagonists for research and potential therapeutic applications [PubChem: Varenicline]. Safety concerns often involve neuropsychiatric effects and gastrointestinal issues due to the widespread distribution of these receptors and their influence on multiple neurotransmitter systems [FDA: Chantix Label].

Other names

CHRNB2Acetylcholine receptor subunit beta-2nAChRB2alpha4beta2 nicotinic receptorCholinergic receptor nicotinic beta 2 subunit

Agonism, partial agonism, antagonism, and positive allosteric modulation of the pentameric ion channel to regulate cation influx and neurotransmitter release [PubMed: 15504151, PubChem: Varenicline].